Assessment of myosin II, Va, VI and VIIa loss of function on endocytosis and endocytic vesicle motility in bone marrow-derived dendritic cells.
An essential feature of dendritic cell immune surveillance is endocytic sampling of the environment for non-self antigens primarily via macropinocytosis and phagocytosis. The role of several members of the myosin family of actin based molecular motors in dendritic cell endocytosis and endocytic vesicle movement was assessed through analysis of dendritic cells derived from mice with functionally null myosin mutations. These include the dilute (myosin Va), Snell's waltzer (myosin VI) and shaker-1 (myosin VIIa) mouse lines. Non muscle myosin II function was assessed by treatment with the inhibitor, blebbistatin. Flow cytometric analysis of dextran uptake by dendritic cells revealed that macropinocytosis was enhanced in Snell's waltzer dendritic cells while shaker-1 and blebbistatin-treated cells were comparable to controls. Comparison of fluid phase uptake using pH insensitive versus pH sensitive fluorescent dextrans revealed that in dilute cells rates of uptake were normal but endosomal acidification was accelerated. Phagocytosis, as quantified by uptake of E. coli, was normal in dilute while dendritic cells from Snell's waltzer, shaker-1 and blebbistatin treated cells exhibited decreased uptake. Microtubule mediated movements of dextran-or transferrin-tagged endocytic vesicles were significantly faster in dendritic cells lacking myosin Va. Loss of myosin II, VI or VIIa function had no significant effects on rates of endocytic vesicle movement.
Holt
Jeffrey P
JP
Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut, USA.
Bottomly
Kim
K
Mooseker
Mark S
MS
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology; D002478:Cells, Cultured; D003599:Cytoskeleton; D003713:Dendritic Cells / Q000166:cytology*; D004705:Endocytosis; D006576:Heterocyclic Compounds, 4 or More Rings / Q000009:adverse effects; D051379:Mice; D008817:Mice, Mutant Strains; D024701:Myosin Type V / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D009218:Myosins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D024507:Nonmuscle Myosin Type IIA / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D010587:Phagocytosis; D010873:Pinocytosis; D022161:Transport Vesicles / Q000502:physiology
D006576:Heterocyclic Compounds, 4 or More Rings; C472645:blebbistatin; D024701:Myosin Type V; D024507:Nonmuscle Myosin Type IIA; D009218:Myosins